Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP raised its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 47.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,606 shares of the company’s stock after purchasing an additional 41,147 shares during the quarter. Trexquant Investment LP’s holdings in Fulgent Genetics were worth $2,375,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp raised its holdings in shares of Fulgent Genetics by 1.4% during the 3rd quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after buying an additional 10,868 shares during the period. Geode Capital Management LLC grew its position in Fulgent Genetics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 514,152 shares of the company’s stock valued at $9,499,000 after acquiring an additional 11,283 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Fulgent Genetics by 39.4% during the fourth quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company’s stock valued at $8,704,000 after purchasing an additional 133,215 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Fulgent Genetics during the third quarter worth $5,854,000. Finally, Barclays PLC boosted its stake in shares of Fulgent Genetics by 22.6% in the third quarter. Barclays PLC now owns 174,855 shares of the company’s stock valued at $3,800,000 after purchasing an additional 32,250 shares during the period. Institutional investors and hedge funds own 48.06% of the company’s stock.

Insider Buying and Selling at Fulgent Genetics

In other news, CFO Paul Kim acquired 100,000 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average price of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the purchase, the chief financial officer now directly owns 348,282 shares of the company’s stock, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Trading Up 1.4 %

FLGT stock opened at $17.10 on Tuesday. The firm has a 50 day simple moving average of $16.80 and a 200-day simple moving average of $18.42. The company has a market capitalization of $527.81 million, a P/E ratio of -3.10 and a beta of 1.36. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $25.11.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on FLGT shares. Piper Sandler dropped their price target on shares of Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. StockNews.com raised Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.